

## Bactiguard Holding AB's interim report first quarter 2025

### Continued profitability and revenue growth for Bactiguard

#### First quarter 2025 (January – March)

- Total revenue amounted to SEK 62.7 (58.8) million, an increase of SEK 3.9 million corresponding to 6.7%.
- Net sales amounted to SEK 59.1 (53.9) million, an increase of SEK 5.1 million corresponding to 9.5%. Adjusted for currency effects of SEK 1.7 million, net sales increased by 6.3%.
- Operating loss amounted to SEK 2.6 (12.9) million.
- EBITDA amounted to SEK 9.4 (-1.5) million.
- Net loss for the period amounted to SEK 4.7 (9.9) million.
- Loss per share, before and after dilution, amounted to SEK 0.13 (0.28).
- Cash flow from operating activities amounted to SEK -12.1 (-19.1) million corresponding to SEK -0.35 (-0.54)

#### Christine Lind, CEO of Bactiguard comments:

“Following the 2024 financial turnaround, we continue our profitable path with yet another strong quarter. EBITDA amounted to SEK 9.4 million (Q1 2024: SEK -1.5 million) and revenues increased by 6.7 percent compared to Q1 last year and landed at SEK 62.7 million (Q1 2024: SEK 58.8 million). Our license business developed well, primarily driven by the successful collaboration with license partner BD, demonstrating a consistent positive financial performance thanks to our strategic transition. The Wound Management portfolio also had a strong quarter with a revenue increase of more than 50 percent, fueled by a significant rise in sales of Hydrocyn aqua. During the quarter, we also updated our strategic and financial targets and core therapeutic areas, areas where our infection prevention solutions can play an important role in addressing the unmet need associated with medical device related infections.”

Bactiguard Holding AB's (publ) report for the first quarter 2025 is available at <https://ir.bactiguard.com/>

*This information is information that Bactiguard Holding AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out below, 2025-04-24 at 07:00 CET.*

#### For further information, please contact:

Patrick Bach, CFO +46 761 295 911

Nina Nornholm, Head of Communications & Investor Relations +46 708 550 356

**To participate in the audiocast, please use this link:** <https://ir.bactiguard.com/report/q1-2025/>

To participate only by conference call, please register on the link above. Questions can be asked either in writing via the audiocast or orally if you attend the conference call.

#### About Bactiguard

*Bactiguard is a global MedTech company developing safe and biocompatible technology to prevent medical device related infections. The unique technology is based on an ultra-thin noble metal coating that prevents bacterial adhesion and biofilm formation on medical devices. The company focuses on five strategic therapeutic areas where infection rates create high medical needs for infection prevention. These areas include Orthopedics, Cardiology, Neurology, Urology, and Vascular Access.*

*Bactiguard operates through license partnerships with leading global MedTech companies that apply the technology to their medical devices. The company also has a portfolio of wound management products. Bactiguard's infection prevention solutions decrease patient suffering, save lives, and unburden healthcare resources while also fighting against antimicrobial resistance, one of the most serious threats to global health and modern medicine. Bactiguard is headquartered in Stockholm and is listed on Nasdaq Stockholm and is included in the Mid-Cap segment.*

Read more about Bactiguard: [www.bactiguard.com](http://www.bactiguard.com)

Follow Bactiguard on [LinkedIn](#)